University of California San Francisco
Give to UCSF
The tobacco industry manipulated the renowned children’s rights agency UNICEF for more than a dozen years, from 2003 until at least 2016, during which time UNICEF’s focus on children’s rights to a tobacco-free life was reduced, according to previously secret documents uncovered by UCSF.
Treating young children in Sub-Saharan Africa with azithromycin, a safe, inexpensive, and widely used antibiotic, significantly reduced deaths of children under five.
A new study from UCSF shows preterm labor may sometimes happen when the fetal immune system “wakes up” too early and begins to reject the mother, causing the uterus to start contracting.
A rear-ender in which the driver’s head slams against the steering wheel or a helmet-to-helmet tussle with an opponent on the football field may increase one’s risk for Parkinson’s disease if concussion results.
New study could make it much easier for physicians to use the genetic profile of a patient’s tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success.
A new study finds that a common cancer-causing mutation in a GTPase called Gαs subverts the model for this type of growth switch in cancer.
A new, large-scale study may help allay concerns of cardiovascular risk from the use of smoking cessation medications.
A newly launched Lancet Commission on Malaria Eradication will convene experts from around the world to develop the first-ever roadmap to eradicate malaria.
Early child care does not boost children’s risk for developing asthma.
The largest analysis to date of genetic data in ALS has identified two previously unrecognized genetic risks that are significantly associated with the disease.
UCSF researchers have shown that an experimental brain boosting drug, ISRIB, acts like a molecular staple, pinning together parts of a much larger protein involved in cellular stress.
The use of newer blood-thinners for patients at risk of stroke may lead to two fewer days in the hospital for those who experience complications, with the same survival rate as the older drug warfarin.
UCSF scientists uncovered a common genetic driver of aggressive meningiomas, which could help clinicians detect dangerous cancers earlier and lead to new therapies.
In the absence of rigorous preclinical testing from the FDA, health systems should carefully scrutinize digital tools that interact with electronic health records to recommend patient diagnoses or therapies.
Ata's appearance can most likely be explained by a handful of rare genetic mutations—some already known, others newly discovered—that are linked to dwarfism and other bone and growth disorders.
